Leveraging advancements in nanotechnology, investigators from the Brigham have found
New therapeutic strategy for chemotherapy resistance in ovarian cancer
A study from The Wistar Institute demonstrated that NAMPT, an
Protein could offer therapeutic target for pancreatic cancer
A protein that drives growth of pancreatic cancer, and which
New therapeutic target for depression identified
Depression is one of the most widespread disorders, and it
Plant compound found to have therapeutic effect on complications from snakebites
Rutin, a flavonoid, may complement antivenom as an effective co-treatment
Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 21, 2018– Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY),